Several effects have been associated with DPP-4, including degradation of various substrates (such as incretins, neuropeptides, and cytokines) and involvement with inflammatory processes (including cancer, obesity, and T2DM, 20, 37)
This is an exciting development, which follows the discovery from CV outcomes trials (CVOTs) that some antidiabetic agents have a cardioprotective effect in at-risk patients [7,8,9,10]
A recent clinical trial, however, demonstrated a 40% reduction in opioid cravings and an overall decrease in self-administration with the GLP-1RA liraglutide
Hence, a significant market opportunity exists for orally dosed small molecules with good bioavailability to address these needs
A study showed that naltrexone and bupropion treatment was associated with a total body weight loss (TBWL) of 5.2%